A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.
Arta M MonjazebAnita Giobbie-HurderAna LakoEmily M ThrashRyan C BrennickKatrina Z KaoClaire ManuszakRyan D GentzlerAnteneh A TesfayeSalma K JabbourOlatunji B AleseOsama E RahmaJames M ClearyElad SharonHarvey J MamonMay ChoHoward StreicherHelen X ChenMansoor M AhmedAdrian Mariño-EnríquezSeunghee Kim-SchulzeSacha GnjaticEmanual MaverakisAlina I MarusinaAlexander A MerleevMariano SevergniniKathleen L PfaffJames R LindsayJason L WeiratherSrinika RanasingheAlexander SpektorScott J RodigStephen F HodiJonathan D SchoenfeldPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
We demonstrate the feasibility and safety of adding LDFRT and HFRT to PD-L1/CTLA-4 blockade. Although the best response of stable disease does not support the use of concurrent PD-L1/CTLA-4 inhibition with HFRT or LDFRT in this population, biomarkers provide support that both LDFRT and HFRT impact the local immune microenvironment and systemic immunogenicity that can help guide future studies.